| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 462 | 2023 | 20988 | 12.390 |
Why?
|
| Receptor, erbB-2 | 146 | 2023 | 2553 | 9.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 189 | 2023 | 11735 | 6.790 |
Why?
|
| Paclitaxel | 69 | 2023 | 1730 | 4.790 |
Why?
|
| Aromatase Inhibitors | 39 | 2021 | 513 | 4.280 |
Why?
|
| Receptors, Estrogen | 77 | 2022 | 2208 | 3.780 |
Why?
|
| Chemotherapy, Adjuvant | 120 | 2022 | 3514 | 3.750 |
Why?
|
| Antineoplastic Agents, Hormonal | 49 | 2022 | 1520 | 3.160 |
Why?
|
| Tamoxifen | 43 | 2022 | 965 | 2.890 |
Why?
|
| Quinazolines | 27 | 2021 | 1371 | 2.460 |
Why?
|
| Antineoplastic Agents | 87 | 2022 | 13635 | 2.420 |
Why?
|
| Neoadjuvant Therapy | 45 | 2022 | 2827 | 2.060 |
Why?
|
| Receptors, Progesterone | 41 | 2022 | 1129 | 2.030 |
Why?
|
| Breast Neoplasms, Male | 9 | 2023 | 212 | 1.790 |
Why?
|
| Carcinoma, Ductal, Breast | 15 | 2022 | 1084 | 1.620 |
Why?
|
| Neoplasm Recurrence, Local | 54 | 2023 | 9277 | 1.610 |
Why?
|
| Brain Neoplasms | 30 | 2023 | 9026 | 1.600 |
Why?
|
| Medical Oncology | 18 | 2021 | 2317 | 1.540 |
Why?
|
| Female | 497 | 2023 | 392203 | 1.470 |
Why?
|
| Disease-Free Survival | 69 | 2022 | 6807 | 1.460 |
Why?
|
| Triazoles | 19 | 2017 | 903 | 1.460 |
Why?
|
| Nitriles | 20 | 2021 | 971 | 1.460 |
Why?
|
| Neoplasm Staging | 97 | 2022 | 11118 | 1.440 |
Why?
|
| Vinblastine | 18 | 2013 | 488 | 1.390 |
Why?
|
| Pyridines | 14 | 2022 | 2875 | 1.230 |
Why?
|
| Neoplasm Metastasis | 63 | 2021 | 4910 | 1.230 |
Why?
|
| Cyclophosphamide | 42 | 2020 | 2218 | 1.170 |
Why?
|
| Mastectomy, Segmental | 22 | 2021 | 955 | 1.150 |
Why?
|
| Humans | 558 | 2023 | 760740 | 1.150 |
Why?
|
| Carboplatin | 11 | 2022 | 793 | 1.130 |
Why?
|
| Fluorouracil | 30 | 2019 | 1642 | 1.130 |
Why?
|
| Doxorubicin | 42 | 2020 | 2224 | 1.110 |
Why?
|
| Antineoplastic Agents, Phytogenic | 13 | 2016 | 620 | 1.100 |
Why?
|
| Middle Aged | 286 | 2023 | 220603 | 1.100 |
Why?
|
| Postmenopause | 24 | 2022 | 2511 | 1.080 |
Why?
|
| Clinical Trials as Topic | 31 | 2020 | 7995 | 1.060 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 12 | 2015 | 926 | 1.050 |
Why?
|
| Deoxycytidine | 19 | 2014 | 878 | 1.040 |
Why?
|
| Aged | 252 | 2022 | 169092 | 1.030 |
Why?
|
| Antibodies, Monoclonal | 31 | 2018 | 9171 | 1.030 |
Why?
|
| Oxazoles | 4 | 2021 | 199 | 0.990 |
Why?
|
| Epothilones | 5 | 2021 | 42 | 0.950 |
Why?
|
| Protein Kinase Inhibitors | 19 | 2022 | 5672 | 0.920 |
Why?
|
| Adult | 249 | 2022 | 220995 | 0.910 |
Why?
|
| Treatment Outcome | 124 | 2023 | 64572 | 0.910 |
Why?
|
| Consensus Development Conferences as Topic | 4 | 2019 | 167 | 0.900 |
Why?
|
| Maytansine | 6 | 2021 | 86 | 0.890 |
Why?
|
| Survival Analysis | 41 | 2022 | 10072 | 0.890 |
Why?
|
| Mammography | 12 | 2021 | 2430 | 0.880 |
Why?
|
| Carcinoma, Lobular | 9 | 2022 | 480 | 0.870 |
Why?
|
| Taxoids | 13 | 2022 | 667 | 0.870 |
Why?
|
| Mastectomy | 33 | 2022 | 1817 | 0.850 |
Why?
|
| Neoplasms, Hormone-Dependent | 9 | 2014 | 410 | 0.840 |
Why?
|
| Albumins | 8 | 2021 | 575 | 0.830 |
Why?
|
| Survivors | 20 | 2021 | 2373 | 0.810 |
Why?
|
| Cisplatin | 13 | 2021 | 1650 | 0.790 |
Why?
|
| Genes, BRCA1 | 18 | 2018 | 753 | 0.780 |
Why?
|
| Quality of Life | 40 | 2022 | 13359 | 0.760 |
Why?
|
| Piperazines | 12 | 2022 | 2521 | 0.700 |
Why?
|
| Drug Resistance, Neoplasm | 26 | 2022 | 5304 | 0.690 |
Why?
|
| Anilides | 3 | 2019 | 411 | 0.680 |
Why?
|
| Antimetabolites, Antineoplastic | 8 | 2019 | 645 | 0.670 |
Why?
|
| Aged, 80 and over | 103 | 2021 | 58919 | 0.670 |
Why?
|
| Prognosis | 65 | 2022 | 29601 | 0.670 |
Why?
|
| Antibiotics, Antineoplastic | 8 | 2021 | 678 | 0.670 |
Why?
|
| Anthracyclines | 12 | 2021 | 285 | 0.660 |
Why?
|
| Disclosure | 4 | 2009 | 747 | 0.660 |
Why?
|
| Drug Administration Schedule | 36 | 2020 | 4845 | 0.640 |
Why?
|
| Kaplan-Meier Estimate | 32 | 2021 | 6473 | 0.630 |
Why?
|
| Interdisciplinary Communication | 5 | 2021 | 928 | 0.630 |
Why?
|
| Trinitrotoluene | 1 | 2018 | 6 | 0.620 |
Why?
|
| Survival Rate | 43 | 2021 | 12719 | 0.620 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 8 | 2016 | 629 | 0.610 |
Why?
|
| Aminopyridines | 8 | 2022 | 573 | 0.610 |
Why?
|
| Exercise Therapy | 4 | 2019 | 929 | 0.610 |
Why?
|
| Lymphatic Metastasis | 27 | 2021 | 2913 | 0.590 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 8 | 2021 | 899 | 0.580 |
Why?
|
| Platinum Compounds | 3 | 2015 | 95 | 0.560 |
Why?
|
| Fertility | 3 | 2008 | 769 | 0.560 |
Why?
|
| Androstadienes | 7 | 2020 | 348 | 0.540 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2020 | 2425 | 0.540 |
Why?
|
| Phthalazines | 6 | 2022 | 383 | 0.540 |
Why?
|
| SEER Program | 20 | 2022 | 1450 | 0.530 |
Why?
|
| Exercise | 9 | 2021 | 5886 | 0.530 |
Why?
|
| Combined Modality Therapy | 34 | 2021 | 8516 | 0.530 |
Why?
|
| Breast | 14 | 2023 | 1963 | 0.530 |
Why?
|
| Enzyme Inhibitors | 9 | 2010 | 3705 | 0.520 |
Why?
|
| Quinolines | 7 | 2022 | 764 | 0.520 |
Why?
|
| Genes, erbB-2 | 7 | 2011 | 162 | 0.520 |
Why?
|
| Neutropenia | 8 | 2022 | 885 | 0.500 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 2021 | 1088 | 0.490 |
Why?
|
| Practice Guidelines as Topic | 14 | 2019 | 7390 | 0.480 |
Why?
|
| Menopause | 7 | 2009 | 1645 | 0.460 |
Why?
|
| Physical Fitness | 3 | 2016 | 743 | 0.460 |
Why?
|
| Mutation | 37 | 2022 | 30015 | 0.450 |
Why?
|
| Peripheral Nervous System Diseases | 6 | 2019 | 709 | 0.450 |
Why?
|
| Neoplasms, Second Primary | 5 | 2016 | 1051 | 0.450 |
Why?
|
| Premenopause | 11 | 2018 | 1038 | 0.440 |
Why?
|
| Body Mass Index | 7 | 2021 | 12942 | 0.430 |
Why?
|
| Randomized Controlled Trials as Topic | 24 | 2018 | 10203 | 0.430 |
Why?
|
| Follow-Up Studies | 50 | 2021 | 39062 | 0.430 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2021 | 8542 | 0.420 |
Why?
|
| Clinical Trials, Phase III as Topic | 7 | 2013 | 857 | 0.420 |
Why?
|
| Ovarian Neoplasms | 14 | 2020 | 4849 | 0.420 |
Why?
|
| Filgrastim | 8 | 2020 | 132 | 0.420 |
Why?
|
| Adaptation, Psychological | 7 | 2014 | 2632 | 0.420 |
Why?
|
| Age Factors | 34 | 2019 | 18381 | 0.410 |
Why?
|
| Dose-Response Relationship, Drug | 27 | 2019 | 10754 | 0.410 |
Why?
|
| Estrogen Receptor Modulators | 5 | 2010 | 58 | 0.400 |
Why?
|
| Genetic Testing | 13 | 2021 | 3533 | 0.400 |
Why?
|
| Colony-Stimulating Factors | 1 | 2012 | 218 | 0.400 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2013 | 915 | 0.400 |
Why?
|
| Lymph Node Excision | 9 | 2017 | 1269 | 0.400 |
Why?
|
| Immunity | 1 | 2018 | 994 | 0.400 |
Why?
|
| Body Weight | 2 | 2021 | 4615 | 0.380 |
Why?
|
| Estrogen Receptor alpha | 4 | 2020 | 583 | 0.380 |
Why?
|
| Attitude of Health Personnel | 7 | 2020 | 3882 | 0.380 |
Why?
|
| Radiotherapy | 12 | 2017 | 1497 | 0.380 |
Why?
|
| Population Surveillance | 4 | 2017 | 2597 | 0.370 |
Why?
|
| Genes, BRCA2 | 8 | 2018 | 590 | 0.360 |
Why?
|
| Disease Progression | 25 | 2021 | 13495 | 0.360 |
Why?
|
| Pneumonia, Pneumocystis | 2 | 2015 | 242 | 0.360 |
Why?
|
| Research Subjects | 4 | 2007 | 249 | 0.360 |
Why?
|
| Decision Making | 8 | 2017 | 3919 | 0.360 |
Why?
|
| Estrogen Antagonists | 4 | 2022 | 150 | 0.350 |
Why?
|
| Palliative Care | 5 | 2020 | 3593 | 0.350 |
Why?
|
| Amenorrhea | 3 | 2021 | 483 | 0.350 |
Why?
|
| Radiotherapy, Adjuvant | 15 | 2019 | 1784 | 0.350 |
Why?
|
| Informed Consent | 4 | 2011 | 1007 | 0.350 |
Why?
|
| Proportional Hazards Models | 23 | 2023 | 12448 | 0.340 |
Why?
|
| Ketones | 2 | 2021 | 183 | 0.340 |
Why?
|
| Furans | 2 | 2021 | 202 | 0.340 |
Why?
|
| United States | 58 | 2021 | 72292 | 0.340 |
Why?
|
| Neoplasms | 27 | 2021 | 22131 | 0.330 |
Why?
|
| Preoperative Care | 6 | 2019 | 2242 | 0.330 |
Why?
|
| Life Style | 3 | 2013 | 3907 | 0.330 |
Why?
|
| Purines | 4 | 2022 | 606 | 0.320 |
Why?
|
| Societies, Medical | 10 | 2020 | 3901 | 0.320 |
Why?
|
| Guidelines as Topic | 2 | 2018 | 1386 | 0.320 |
Why?
|
| Endpoint Determination | 3 | 2021 | 590 | 0.320 |
Why?
|
| Bone Marrow Transplantation | 4 | 2005 | 2690 | 0.320 |
Why?
|
| Physical Endurance | 2 | 2009 | 366 | 0.320 |
Why?
|
| Thiazoles | 6 | 2022 | 1517 | 0.310 |
Why?
|
| Cyclin-Dependent Kinase 4 | 5 | 2022 | 561 | 0.310 |
Why?
|
| Neoplastic Cells, Circulating | 4 | 2021 | 943 | 0.310 |
Why?
|
| Neoplasm Proteins | 6 | 2010 | 3607 | 0.290 |
Why?
|
| Neoplasm Invasiveness | 11 | 2019 | 3593 | 0.290 |
Why?
|
| Breast Diseases | 2 | 2007 | 443 | 0.290 |
Why?
|
| Biopsy | 9 | 2022 | 6763 | 0.290 |
Why?
|
| Molecular Targeted Therapy | 9 | 2018 | 2812 | 0.290 |
Why?
|
| Maximum Tolerated Dose | 9 | 2021 | 883 | 0.290 |
Why?
|
| Cohort Studies | 36 | 2023 | 41464 | 0.280 |
Why?
|
| Healthcare Disparities | 7 | 2015 | 3351 | 0.280 |
Why?
|
| Time Factors | 33 | 2022 | 39908 | 0.280 |
Why?
|
| Sentinel Lymph Node Biopsy | 8 | 2017 | 732 | 0.280 |
Why?
|
| Estrogens | 2 | 2021 | 1521 | 0.280 |
Why?
|
| Ovary | 2 | 2016 | 959 | 0.280 |
Why?
|
| Medication Adherence | 4 | 2014 | 2175 | 0.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 7 | 2020 | 4010 | 0.270 |
Why?
|
| Morpholines | 3 | 2020 | 581 | 0.270 |
Why?
|
| Prospective Studies | 39 | 2023 | 54364 | 0.270 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2022 | 3611 | 0.270 |
Why?
|
| Genomics | 7 | 2021 | 5822 | 0.270 |
Why?
|
| Patient Participation | 7 | 2015 | 1443 | 0.270 |
Why?
|
| Polyethylene Glycols | 6 | 2020 | 1182 | 0.260 |
Why?
|
| Carcinoma in Situ | 2 | 2010 | 791 | 0.260 |
Why?
|
| Repressor Proteins | 2 | 2017 | 2985 | 0.260 |
Why?
|
| Neoplasm, Residual | 5 | 2022 | 1008 | 0.260 |
Why?
|
| Health Care Reform | 2 | 2012 | 1247 | 0.260 |
Why?
|
| Young Adult | 35 | 2021 | 59191 | 0.260 |
Why?
|
| Biomedical Research | 7 | 2020 | 3426 | 0.260 |
Why?
|
| Risk Factors | 43 | 2022 | 74128 | 0.260 |
Why?
|
| Carcinoma | 4 | 2015 | 2328 | 0.260 |
Why?
|
| BRCA1 Protein | 6 | 2022 | 1149 | 0.260 |
Why?
|
| Cyclin-Dependent Kinase 6 | 3 | 2018 | 350 | 0.250 |
Why?
|
| Lymph Nodes | 8 | 2019 | 3461 | 0.250 |
Why?
|
| Patient Care Team | 8 | 2013 | 2515 | 0.250 |
Why?
|
| Referral and Consultation | 4 | 2020 | 3599 | 0.250 |
Why?
|
| Carbazoles | 1 | 2006 | 220 | 0.240 |
Why?
|
| Ki-67 Antigen | 5 | 2021 | 627 | 0.240 |
Why?
|
| BRCA2 Protein | 5 | 2020 | 797 | 0.240 |
Why?
|
| Double-Blind Method | 11 | 2020 | 12333 | 0.240 |
Why?
|
| Infusions, Intravenous | 9 | 2020 | 2214 | 0.230 |
Why?
|
| Logistic Models | 17 | 2021 | 13248 | 0.230 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2021 | 17878 | 0.230 |
Why?
|
| Tumor Microenvironment | 6 | 2021 | 3868 | 0.230 |
Why?
|
| Remission Induction | 6 | 2016 | 2391 | 0.220 |
Why?
|
| Erythropoietin | 2 | 2005 | 719 | 0.220 |
Why?
|
| Muscle Strength | 1 | 2008 | 624 | 0.220 |
Why?
|
| Patient Compliance | 4 | 2012 | 2688 | 0.220 |
Why?
|
| Administration, Oral | 11 | 2019 | 4010 | 0.220 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2014 | 1405 | 0.220 |
Why?
|
| Arthralgia | 1 | 2007 | 461 | 0.220 |
Why?
|
| Patient Selection | 11 | 2020 | 4237 | 0.220 |
Why?
|
| Loss of Heterozygosity | 3 | 2016 | 662 | 0.210 |
Why?
|
| Chromans | 1 | 2003 | 117 | 0.210 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2020 | 1113 | 0.210 |
Why?
|
| Cytarabine | 1 | 2005 | 697 | 0.210 |
Why?
|
| Benzamides | 4 | 2020 | 1371 | 0.210 |
Why?
|
| Insurance, Health | 2 | 2012 | 2495 | 0.210 |
Why?
|
| Survival | 2 | 2003 | 161 | 0.210 |
Why?
|
| Gene Expression Profiling | 14 | 2021 | 9417 | 0.210 |
Why?
|
| Phosphatidylinositol 3-Kinases | 6 | 2022 | 2863 | 0.210 |
Why?
|
| Patient Satisfaction | 6 | 2013 | 3451 | 0.210 |
Why?
|
| Anxiety | 8 | 2015 | 4573 | 0.200 |
Why?
|
| DNA Copy Number Variations | 5 | 2021 | 2020 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2020 | 3492 | 0.200 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2016 | 1394 | 0.200 |
Why?
|
| Sarcoidosis | 1 | 2007 | 520 | 0.200 |
Why?
|
| Socioeconomic Factors | 9 | 2020 | 7805 | 0.190 |
Why?
|
| Ethics, Clinical | 1 | 2002 | 101 | 0.190 |
Why?
|
| Estradiol | 4 | 2019 | 1937 | 0.190 |
Why?
|
| Anemia | 3 | 2007 | 1504 | 0.190 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2020 | 257 | 0.190 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 888 | 0.190 |
Why?
|
| Markov Chains | 7 | 2011 | 965 | 0.190 |
Why?
|
| Continuity of Patient Care | 2 | 2005 | 1067 | 0.190 |
Why?
|
| Weight Gain | 6 | 2010 | 2349 | 0.190 |
Why?
|
| Obesity | 2 | 2021 | 12934 | 0.190 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2009 | 1626 | 0.190 |
Why?
|
| Attitude to Health | 4 | 2005 | 2025 | 0.190 |
Why?
|
| Methotrexate | 10 | 2019 | 1716 | 0.190 |
Why?
|
| Germ-Line Mutation | 3 | 2021 | 1852 | 0.180 |
Why?
|
| Fibroblast Growth Factor 3 | 1 | 2020 | 17 | 0.180 |
Why?
|
| Perception | 4 | 2013 | 1199 | 0.180 |
Why?
|
| Cytochrome P-450 CYP2D6 | 2 | 2013 | 107 | 0.180 |
Why?
|
| Risk Assessment | 20 | 2021 | 23974 | 0.180 |
Why?
|
| Spouses | 1 | 2003 | 283 | 0.180 |
Why?
|
| Consensus | 3 | 2020 | 3117 | 0.180 |
Why?
|
| Research Design | 5 | 2021 | 6174 | 0.180 |
Why?
|
| Risk | 7 | 2020 | 9603 | 0.180 |
Why?
|
| Predictive Value of Tests | 15 | 2021 | 15250 | 0.180 |
Why?
|
| Adenocarcinoma | 3 | 2015 | 6345 | 0.180 |
Why?
|
| Diarrhea | 3 | 2019 | 1317 | 0.180 |
Why?
|
| Pyrazoles | 2 | 2021 | 2008 | 0.170 |
Why?
|
| Patient Care Planning | 1 | 2005 | 905 | 0.170 |
Why?
|
| Patient Advocacy | 2 | 2015 | 360 | 0.170 |
Why?
|
| Receptors, Steroid | 3 | 2020 | 156 | 0.170 |
Why?
|
| Thiazolidinediones | 1 | 2003 | 460 | 0.170 |
Why?
|
| Phenylthiohydantoin | 2 | 2020 | 205 | 0.170 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2003 | 563 | 0.170 |
Why?
|
| Inflammatory Breast Neoplasms | 2 | 2019 | 147 | 0.170 |
Why?
|
| Fatigue | 6 | 2015 | 1550 | 0.170 |
Why?
|
| Registries | 6 | 2023 | 8209 | 0.170 |
Why?
|
| Clinical Trials, Phase II as Topic | 6 | 2015 | 629 | 0.170 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2014 | 487 | 0.170 |
Why?
|
| Multivariate Analysis | 14 | 2019 | 12043 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2020 | 120 | 0.170 |
Why?
|
| Recurrence | 6 | 2019 | 8426 | 0.160 |
Why?
|
| Antigens, CD20 | 2 | 2011 | 199 | 0.160 |
Why?
|
| Drug Delivery Systems | 2 | 2008 | 2222 | 0.160 |
Why?
|
| Transplantation, Autologous | 3 | 2005 | 2112 | 0.160 |
Why?
|
| Recombinant Proteins | 9 | 2010 | 6520 | 0.160 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2020 | 214 | 0.160 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2019 | 287 | 0.160 |
Why?
|
| Life Expectancy | 3 | 2021 | 1242 | 0.160 |
Why?
|
| Interpersonal Relations | 1 | 2006 | 1438 | 0.160 |
Why?
|
| Male | 49 | 2023 | 360402 | 0.160 |
Why?
|
| Truth Disclosure | 1 | 2003 | 432 | 0.160 |
Why?
|
| Tegafur | 1 | 1998 | 39 | 0.160 |
Why?
|
| Radiosurgery | 2 | 2021 | 1339 | 0.160 |
Why?
|
| Pilot Projects | 11 | 2019 | 8619 | 0.150 |
Why?
|
| Cell Proliferation | 8 | 2021 | 10429 | 0.150 |
Why?
|
| Complementary Therapies | 1 | 2002 | 486 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 4 | 2013 | 1700 | 0.150 |
Why?
|
| Phenotype | 1 | 2016 | 16572 | 0.150 |
Why?
|
| Sensory Receptor Cells | 2 | 2014 | 508 | 0.150 |
Why?
|
| Indoles | 1 | 2006 | 1830 | 0.150 |
Why?
|
| Amifostine | 3 | 2003 | 40 | 0.150 |
Why?
|
| Pyrimidinones | 1 | 2020 | 385 | 0.150 |
Why?
|
| Endometrial Neoplasms | 1 | 2007 | 1365 | 0.150 |
Why?
|
| Janus Kinase 2 | 1 | 2021 | 560 | 0.150 |
Why?
|
| Patient Education as Topic | 7 | 2012 | 2315 | 0.150 |
Why?
|
| Pathology, Surgical | 2 | 2009 | 151 | 0.150 |
Why?
|
| Axilla | 7 | 2017 | 624 | 0.150 |
Why?
|
| Poisson Distribution | 1 | 2019 | 504 | 0.150 |
Why?
|
| Salvage Therapy | 5 | 2016 | 1263 | 0.150 |
Why?
|
| Meningeal Neoplasms | 2 | 2004 | 1245 | 0.140 |
Why?
|
| Body Image | 2 | 2012 | 639 | 0.140 |
Why?
|
| Retrospective Studies | 33 | 2023 | 80583 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2016 | 2048 | 0.140 |
Why?
|
| Uracil | 1 | 1998 | 207 | 0.140 |
Why?
|
| Integrative Medicine | 1 | 2018 | 87 | 0.140 |
Why?
|
| Quality of Health Care | 3 | 2009 | 4325 | 0.140 |
Why?
|
| Epirubicin | 3 | 2013 | 81 | 0.140 |
Why?
|
| Research Support as Topic | 3 | 2012 | 697 | 0.140 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 3410 | 0.140 |
Why?
|
| Leukemia, Myeloid | 1 | 2020 | 693 | 0.140 |
Why?
|
| Evidence-Based Medicine | 7 | 2018 | 3680 | 0.140 |
Why?
|
| Silicones | 2 | 1996 | 228 | 0.130 |
Why?
|
| Patients | 1 | 2003 | 906 | 0.130 |
Why?
|
| Primary Ovarian Insufficiency | 2 | 2011 | 107 | 0.130 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2020 | 495 | 0.130 |
Why?
|
| Basal Metabolism | 1 | 1997 | 161 | 0.130 |
Why?
|
| Fluorodeoxyglucose F18 | 4 | 2021 | 2008 | 0.130 |
Why?
|
| Camptothecin | 2 | 2023 | 591 | 0.130 |
Why?
|
| Immunohistochemistry | 10 | 2021 | 11069 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2020 | 2456 | 0.130 |
Why?
|
| Heart Diseases | 5 | 2010 | 2778 | 0.130 |
Why?
|
| Cell Line, Tumor | 12 | 2020 | 16968 | 0.130 |
Why?
|
| Small Molecule Libraries | 1 | 2021 | 733 | 0.130 |
Why?
|
| Allelic Imbalance | 1 | 2016 | 77 | 0.130 |
Why?
|
| Communication | 2 | 2008 | 3851 | 0.130 |
Why?
|
| Drug Therapy | 1 | 1999 | 503 | 0.130 |
Why?
|
| Hospitals | 1 | 2009 | 3879 | 0.130 |
Why?
|
| Attitude | 1 | 2020 | 772 | 0.130 |
Why?
|
| Cell Cycle Proteins | 4 | 2020 | 3447 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2016 | 571 | 0.130 |
Why?
|
| Testicular Neoplasms | 1 | 2021 | 800 | 0.120 |
Why?
|
| Focus Groups | 2 | 2000 | 1409 | 0.120 |
Why?
|
| Immunoconjugates | 1 | 2023 | 951 | 0.120 |
Why?
|
| Myeloproliferative Disorders | 1 | 2021 | 611 | 0.120 |
Why?
|
| Women's Health | 3 | 2012 | 2066 | 0.120 |
Why?
|
| Pneumocystis carinii | 1 | 2015 | 72 | 0.120 |
Why?
|
| Europe | 3 | 2018 | 3415 | 0.120 |
Why?
|
| Pyrrolidinones | 1 | 2015 | 116 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2020 | 3634 | 0.120 |
Why?
|
| Adolescent | 19 | 2021 | 88247 | 0.120 |
Why?
|
| Research | 3 | 2013 | 1977 | 0.120 |
Why?
|
| Decision Support Techniques | 6 | 2008 | 1999 | 0.120 |
Why?
|
| Body Height | 1 | 2021 | 1565 | 0.120 |
Why?
|
| Opportunistic Infections | 2 | 2015 | 376 | 0.120 |
Why?
|
| Nurses | 1 | 2004 | 2477 | 0.120 |
Why?
|
| Disease Susceptibility | 2 | 2018 | 1788 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2018 | 548 | 0.110 |
Why?
|
| Prescription Fees | 1 | 2015 | 153 | 0.110 |
Why?
|
| Odds Ratio | 9 | 2016 | 9644 | 0.110 |
Why?
|
| Medical History Taking | 2 | 1998 | 773 | 0.110 |
Why?
|
| Reproductive History | 1 | 2015 | 210 | 0.110 |
Why?
|
| Platinum | 3 | 2021 | 220 | 0.110 |
Why?
|
| Receptors, Androgen | 2 | 2018 | 1079 | 0.110 |
Why?
|
| Tretinoin | 1 | 1997 | 519 | 0.110 |
Why?
|
| Treatment Failure | 4 | 2014 | 2635 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2016 | 546 | 0.110 |
Why?
|
| Azepines | 1 | 2016 | 329 | 0.110 |
Why?
|
| Transcription Factors | 5 | 2022 | 12116 | 0.110 |
Why?
|
| Endocrine System | 1 | 2014 | 114 | 0.110 |
Why?
|
| Family | 4 | 2002 | 3193 | 0.110 |
Why?
|
| Inflammation | 2 | 2012 | 10759 | 0.110 |
Why?
|
| Insulin | 1 | 2008 | 6593 | 0.110 |
Why?
|
| Hormones | 4 | 2022 | 869 | 0.110 |
Why?
|
| Gene Expression | 2 | 2016 | 7569 | 0.110 |
Why?
|
| Drug Synergism | 3 | 2010 | 1756 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2013 | 558 | 0.110 |
Why?
|
| Multiprotein Complexes | 2 | 2016 | 1118 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 3 | 2015 | 2644 | 0.110 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2014 | 125 | 0.100 |
Why?
|
| Tumor Burden | 5 | 2019 | 1892 | 0.100 |
Why?
|
| Telemedicine | 1 | 2010 | 3051 | 0.100 |
Why?
|
| Alleles | 3 | 2018 | 6861 | 0.100 |
Why?
|
| Liposomes | 5 | 2004 | 784 | 0.100 |
Why?
|
| Quinoxalines | 1 | 2014 | 296 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2011 | 3776 | 0.100 |
Why?
|
| Self-Help Groups | 1 | 2014 | 192 | 0.100 |
Why?
|
| Comorbidity | 9 | 2015 | 10507 | 0.100 |
Why?
|
| Chromatin | 3 | 2022 | 2955 | 0.100 |
Why?
|
| Portugal | 1 | 2012 | 91 | 0.100 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2016 | 2057 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2020 | 3599 | 0.100 |
Why?
|
| Congresses as Topic | 4 | 2011 | 802 | 0.100 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 431 | 0.100 |
Why?
|
| Immunotoxins | 1 | 2012 | 175 | 0.100 |
Why?
|
| Carmustine | 3 | 2005 | 137 | 0.100 |
Why?
|
| DNA Repair | 2 | 2018 | 2043 | 0.100 |
Why?
|
| Radiation Oncology | 1 | 2018 | 563 | 0.100 |
Why?
|
| Mass Screening | 4 | 2021 | 5425 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 2 | 2015 | 1483 | 0.100 |
Why?
|
| Physicians | 3 | 2015 | 4583 | 0.100 |
Why?
|
| Delayed Diagnosis | 2 | 2013 | 463 | 0.100 |
Why?
|
| Standard of Care | 1 | 2015 | 551 | 0.100 |
Why?
|
| Patient Preference | 2 | 2017 | 925 | 0.100 |
Why?
|
| Cranial Irradiation | 1 | 2014 | 390 | 0.090 |
Why?
|
| Drug Substitution | 1 | 2014 | 290 | 0.090 |
Why?
|
| Regression Analysis | 4 | 2014 | 6339 | 0.090 |
Why?
|
| Mesna | 2 | 2002 | 62 | 0.090 |
Why?
|
| Razoxane | 2 | 2002 | 43 | 0.090 |
Why?
|
| Societies | 1 | 2012 | 107 | 0.090 |
Why?
|
| Environment Design | 1 | 2013 | 173 | 0.090 |
Why?
|
| Medicare | 9 | 2018 | 6774 | 0.090 |
Why?
|
| Nausea | 3 | 2013 | 679 | 0.090 |
Why?
|
| Cancer Care Facilities | 2 | 2020 | 422 | 0.090 |
Why?
|
| Topotecan | 1 | 2011 | 131 | 0.090 |
Why?
|
| Physician-Patient Relations | 5 | 2011 | 3239 | 0.090 |
Why?
|
| Tissue Donors | 1 | 2020 | 2329 | 0.090 |
Why?
|
| Telephone | 2 | 2014 | 626 | 0.090 |
Why?
|
| Radiation-Protective Agents | 2 | 2002 | 88 | 0.090 |
Why?
|
| Incidence | 9 | 2016 | 21339 | 0.090 |
Why?
|
| Sleep Disorders, Intrinsic | 1 | 2010 | 16 | 0.090 |
Why?
|
| Antigens, Neoplasm | 2 | 2009 | 1985 | 0.090 |
Why?
|
| Prednisone | 4 | 2014 | 1562 | 0.090 |
Why?
|
| International Cooperation | 3 | 2012 | 1422 | 0.090 |
Why?
|
| Stroke Volume | 3 | 2016 | 5486 | 0.090 |
Why?
|
| Longitudinal Studies | 5 | 2014 | 14599 | 0.090 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2016 | 974 | 0.090 |
Why?
|
| Inservice Training | 1 | 2013 | 375 | 0.090 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2019 | 1158 | 0.090 |
Why?
|
| Benzothiazoles | 1 | 2011 | 247 | 0.090 |
Why?
|
| Expert Testimony | 3 | 2019 | 364 | 0.090 |
Why?
|
| Advisory Committees | 3 | 2009 | 787 | 0.090 |
Why?
|
| Cyclohexanols | 1 | 2010 | 126 | 0.090 |
Why?
|
| Phenylurea Compounds | 1 | 2013 | 529 | 0.090 |
Why?
|
| Gene Amplification | 3 | 2010 | 1087 | 0.090 |
Why?
|
| Ovariectomy | 3 | 2014 | 613 | 0.090 |
Why?
|
| Protective Agents | 2 | 2002 | 150 | 0.090 |
Why?
|
| Piperidines | 2 | 2012 | 1655 | 0.080 |
Why?
|
| Megestrol Acetate | 2 | 2000 | 18 | 0.080 |
Why?
|
| Early Detection of Cancer | 6 | 2021 | 3196 | 0.080 |
Why?
|
| Data Collection | 6 | 2013 | 3316 | 0.080 |
Why?
|
| Sexual Behavior | 3 | 2012 | 2187 | 0.080 |
Why?
|
| Genotype | 4 | 2019 | 12977 | 0.080 |
Why?
|
| Signal Transduction | 9 | 2021 | 23415 | 0.080 |
Why?
|
| Telomere | 1 | 2016 | 942 | 0.080 |
Why?
|
| Factor V | 1 | 2010 | 167 | 0.080 |
Why?
|
| Phosphorylation | 5 | 2021 | 8311 | 0.080 |
Why?
|
| Intention to Treat Analysis | 2 | 2022 | 413 | 0.080 |
Why?
|
| Massachusetts | 3 | 2012 | 8835 | 0.080 |
Why?
|
| Body Composition | 3 | 2008 | 2426 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2021 | 3672 | 0.080 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2014 | 687 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2020 | 15908 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 1 | 2016 | 3793 | 0.080 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 2527 | 0.080 |
Why?
|
| Drug Costs | 2 | 2015 | 1183 | 0.080 |
Why?
|
| Reference Values | 1 | 2016 | 4919 | 0.080 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2009 | 122 | 0.080 |
Why?
|
| Financing, Government | 2 | 2009 | 472 | 0.080 |
Why?
|
| Macrophages | 2 | 2021 | 5758 | 0.080 |
Why?
|
| Bone Density | 2 | 2012 | 3548 | 0.080 |
Why?
|
| Cytoskeletal Proteins | 1 | 2014 | 1336 | 0.080 |
Why?
|
| Ambulatory Care | 3 | 2007 | 2768 | 0.080 |
Why?
|
| Health Status Disparities | 4 | 2015 | 1846 | 0.080 |
Why?
|
| Selective Estrogen Receptor Modulators | 4 | 2010 | 131 | 0.080 |
Why?
|
| DNA Damage | 1 | 2018 | 2445 | 0.080 |
Why?
|
| California | 1 | 2012 | 1431 | 0.080 |
Why?
|
| Therapies, Investigational | 1 | 2008 | 111 | 0.070 |
Why?
|
| Liver Neoplasms | 4 | 2018 | 4309 | 0.070 |
Why?
|
| Feasibility Studies | 7 | 2019 | 5239 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2016 | 2509 | 0.070 |
Why?
|
| Hot Flashes | 1 | 2010 | 330 | 0.070 |
Why?
|
| Heterozygote | 5 | 2015 | 2780 | 0.070 |
Why?
|
| Interferon Regulatory Factors | 1 | 2009 | 261 | 0.070 |
Why?
|
| Urogenital Neoplasms | 1 | 2008 | 131 | 0.070 |
Why?
|
| Primary Health Care | 4 | 2007 | 4677 | 0.070 |
Why?
|
| Animals | 19 | 2022 | 168202 | 0.070 |
Why?
|
| Prevalence | 7 | 2020 | 15702 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2016 | 2896 | 0.070 |
Why?
|
| Educational Status | 4 | 2012 | 2509 | 0.070 |
Why?
|
| Reality Therapy | 1 | 2006 | 5 | 0.070 |
Why?
|
| Thrombocytopenia | 2 | 2014 | 1182 | 0.070 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2016 | 2118 | 0.070 |
Why?
|
| Resistance Training | 1 | 2009 | 193 | 0.070 |
Why?
|
| Waist-Hip Ratio | 1 | 2008 | 518 | 0.070 |
Why?
|
| Prostheses and Implants | 1 | 1993 | 1269 | 0.070 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2008 | 296 | 0.070 |
Why?
|
| Troponin I | 1 | 2011 | 650 | 0.070 |
Why?
|
| Benzimidazoles | 2 | 2021 | 858 | 0.070 |
Why?
|
| Lymphopenia | 1 | 2008 | 281 | 0.070 |
Why?
|
| Ventricular Function, Left | 3 | 2016 | 3873 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2020 | 36401 | 0.070 |
Why?
|
| Diphosphonates | 1 | 2011 | 635 | 0.070 |
Why?
|
| Axons | 1 | 2014 | 1671 | 0.060 |
Why?
|
| Anthropometry | 1 | 2010 | 1338 | 0.060 |
Why?
|
| Multifactorial Inheritance | 1 | 2014 | 1381 | 0.060 |
Why?
|
| Ligands | 2 | 2022 | 3268 | 0.060 |
Why?
|
| Blood Cell Count | 1 | 2006 | 397 | 0.060 |
Why?
|
| Fertility Agents | 1 | 2005 | 11 | 0.060 |
Why?
|
| Leukemia | 2 | 2006 | 1520 | 0.060 |
Why?
|
| Preventive Medicine | 1 | 2007 | 245 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2006 | 375 | 0.060 |
Why?
|
| Genetic Heterogeneity | 2 | 2021 | 733 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2006 | 410 | 0.060 |
Why?
|
| Drug Utilization | 2 | 2002 | 1186 | 0.060 |
Why?
|
| Neoplasm Transplantation | 2 | 2021 | 2010 | 0.060 |
Why?
|
| Antiemetics | 1 | 2006 | 186 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2015 | 2916 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2014 | 1977 | 0.060 |
Why?
|
| Imidazoles | 1 | 2011 | 1175 | 0.060 |
Why?
|
| Daunorubicin | 1 | 2004 | 157 | 0.060 |
Why?
|
| Apoptosis | 2 | 2021 | 9476 | 0.060 |
Why?
|
| Radiopharmaceuticals | 3 | 2021 | 2650 | 0.060 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 5144 | 0.060 |
Why?
|
| Stress, Psychological | 3 | 2012 | 4488 | 0.060 |
Why?
|
| Social Class | 2 | 2010 | 1993 | 0.060 |
Why?
|
| Comprehension | 2 | 2007 | 620 | 0.060 |
Why?
|
| Health Services Accessibility | 4 | 2020 | 5430 | 0.060 |
Why?
|
| Lung Neoplasms | 6 | 2018 | 13383 | 0.060 |
Why?
|
| Genome, Human | 4 | 2021 | 4421 | 0.060 |
Why?
|
| Pandemics | 2 | 2021 | 8652 | 0.060 |
Why?
|
| Sirolimus | 1 | 2011 | 1533 | 0.060 |
Why?
|
| Genetic Markers | 4 | 1999 | 2601 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2020 | 4642 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2009 | 701 | 0.060 |
Why?
|
| Depression | 5 | 2012 | 8132 | 0.060 |
Why?
|
| Mitotic Index | 2 | 2017 | 162 | 0.060 |
Why?
|
| Antigen Presentation | 2 | 2021 | 1250 | 0.060 |
Why?
|
| North Carolina | 2 | 2002 | 322 | 0.060 |
Why?
|
| Forecasting | 3 | 2008 | 2924 | 0.060 |
Why?
|
| Social Adjustment | 1 | 2006 | 632 | 0.060 |
Why?
|
| Nurse-Patient Relations | 1 | 2004 | 99 | 0.060 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2011 | 1372 | 0.060 |
Why?
|
| Hydroxyurea | 1 | 2005 | 282 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2006 | 1810 | 0.060 |
Why?
|
| Models, Organizational | 1 | 2007 | 544 | 0.060 |
Why?
|
| Thromboembolism | 1 | 2010 | 991 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2016 | 3045 | 0.060 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2005 | 349 | 0.050 |
Why?
|
| Nanoparticles | 1 | 2015 | 1957 | 0.050 |
Why?
|
| Unnecessary Procedures | 1 | 2007 | 414 | 0.050 |
Why?
|
| Bone Density Conservation Agents | 1 | 2011 | 794 | 0.050 |
Why?
|
| Genital Neoplasms, Female | 1 | 2008 | 532 | 0.050 |
Why?
|
| Nuclear Proteins | 2 | 2016 | 5789 | 0.050 |
Why?
|
| Xerostomia | 1 | 2003 | 94 | 0.050 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2014 | 1148 | 0.050 |
Why?
|
| Fever | 2 | 2011 | 1618 | 0.050 |
Why?
|
| Positron-Emission Tomography | 4 | 2017 | 6483 | 0.050 |
Why?
|
| DNA Mutational Analysis | 3 | 2016 | 4110 | 0.050 |
Why?
|
| Emigrants and Immigrants | 1 | 2009 | 544 | 0.050 |
Why?
|
| Cross-Over Studies | 3 | 2020 | 2079 | 0.050 |
Why?
|
| Ovulation Induction | 1 | 2005 | 277 | 0.050 |
Why?
|
| Alopecia | 1 | 2007 | 412 | 0.050 |
Why?
|
| Mice | 10 | 2022 | 81368 | 0.050 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2003 | 86 | 0.050 |
Why?
|
| Health Care Costs | 2 | 2008 | 3238 | 0.050 |
Why?
|
| Drug Therapy, Combination | 4 | 2016 | 6305 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2017 | 3527 | 0.050 |
Why?
|
| Constipation | 1 | 2007 | 563 | 0.050 |
Why?
|
| Anticarcinogenic Agents | 1 | 2004 | 249 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2010 | 1178 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2007 | 728 | 0.050 |
Why?
|
| Parity | 2 | 2015 | 924 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 4 | 2007 | 1723 | 0.050 |
Why?
|
| Blood Platelets | 1 | 2012 | 2478 | 0.050 |
Why?
|
| Health Services Research | 1 | 2009 | 1808 | 0.050 |
Why?
|
| Patient Rights | 1 | 2002 | 125 | 0.050 |
Why?
|
| Demography | 1 | 2006 | 1643 | 0.050 |
Why?
|
| Vincristine | 3 | 2014 | 1036 | 0.050 |
Why?
|
| Drug Interactions | 2 | 2009 | 1415 | 0.050 |
Why?
|
| Analysis of Variance | 4 | 2020 | 6223 | 0.050 |
Why?
|
| Genomic Instability | 2 | 2016 | 709 | 0.050 |
Why?
|
| Insurance Coverage | 2 | 2010 | 1937 | 0.050 |
Why?
|
| Thiotepa | 1 | 2001 | 66 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2007 | 786 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2016 | 20556 | 0.050 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2001 | 70 | 0.050 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2008 | 955 | 0.050 |
Why?
|
| Leptin | 1 | 2009 | 1595 | 0.050 |
Why?
|
| Biomarkers, Pharmacological | 2 | 2012 | 161 | 0.050 |
Why?
|
| Models, Biological | 3 | 2018 | 9461 | 0.050 |
Why?
|
| Accidents, Traffic | 1 | 2006 | 816 | 0.050 |
Why?
|
| Premedication | 1 | 2021 | 245 | 0.050 |
Why?
|
| Progestins | 1 | 2003 | 301 | 0.050 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2007 | 1431 | 0.050 |
Why?
|
| Gadolinium | 1 | 2006 | 959 | 0.050 |
Why?
|
| Organizational Policy | 1 | 2003 | 432 | 0.040 |
Why?
|
| Erythrocyte Transfusion | 1 | 2005 | 568 | 0.040 |
Why?
|
| Chelating Agents | 1 | 2002 | 387 | 0.040 |
Why?
|
| Hospice Care | 1 | 2007 | 677 | 0.040 |
Why?
|
| Algorithms | 5 | 2012 | 14024 | 0.040 |
Why?
|
| Drug Industry | 1 | 2007 | 788 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2006 | 1392 | 0.040 |
Why?
|
| Genetic Counseling | 2 | 2002 | 627 | 0.040 |
Why?
|
| Social Support | 2 | 2008 | 2174 | 0.040 |
Why?
|
| Cross-Sectional Studies | 7 | 2013 | 26065 | 0.040 |
Why?
|
| Mammaplasty | 3 | 2013 | 1232 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2006 | 1397 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 2 | 2007 | 751 | 0.040 |
Why?
|
| Mice, Transgenic | 3 | 2018 | 9526 | 0.040 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2020 | 101 | 0.040 |
Why?
|
| Publishing | 1 | 2007 | 832 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2009 | 2092 | 0.040 |
Why?
|
| Disease Management | 3 | 2015 | 2506 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 2003 | 429 | 0.040 |
Why?
|
| Genome-Wide Association Study | 3 | 2015 | 12661 | 0.040 |
Why?
|
| Polyesters | 1 | 2001 | 371 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 1999 | 148 | 0.040 |
Why?
|
| Neuroendocrine Tumors | 1 | 2005 | 641 | 0.040 |
Why?
|
| Heart Failure | 4 | 2013 | 11670 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2006 | 983 | 0.040 |
Why?
|
| Drug Monitoring | 2 | 2019 | 960 | 0.040 |
Why?
|
| Fractures, Bone | 1 | 2011 | 2045 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2001 | 407 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2006 | 1946 | 0.040 |
Why?
|
| Hematologic Diseases | 2 | 2001 | 496 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2011 | 3820 | 0.040 |
Why?
|
| Early Diagnosis | 2 | 2017 | 1185 | 0.040 |
Why?
|
| Staurosporine | 1 | 2020 | 242 | 0.040 |
Why?
|
| Proteomics | 3 | 2020 | 3836 | 0.040 |
Why?
|
| Calcinosis | 1 | 2007 | 1469 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2022 | 697 | 0.040 |
Why?
|
| Chromosome Mapping | 2 | 1998 | 4611 | 0.040 |
Why?
|
| Affect | 1 | 2006 | 1486 | 0.040 |
Why?
|
| Thiophenes | 1 | 2003 | 569 | 0.040 |
Why?
|
| Epidermal Growth Factor | 1 | 2021 | 699 | 0.040 |
Why?
|
| Blood Donors | 1 | 2020 | 345 | 0.040 |
Why?
|
| Aminoglycosides | 1 | 1999 | 160 | 0.040 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 20077 | 0.040 |
Why?
|
| Vesicular Transport Proteins | 1 | 2021 | 376 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2020 | 318 | 0.040 |
Why?
|
| DNA-Binding Proteins | 3 | 2012 | 9586 | 0.040 |
Why?
|
| Blood-Brain Barrier | 2 | 2018 | 1027 | 0.040 |
Why?
|
| Pain | 4 | 2011 | 5062 | 0.040 |
Why?
|
| Hematinics | 1 | 2001 | 282 | 0.040 |
Why?
|
| Mind-Body Therapies | 1 | 2021 | 279 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2005 | 1725 | 0.040 |
Why?
|
| Cognition Disorders | 2 | 2004 | 3979 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2003 | 566 | 0.040 |
Why?
|
| Community-Based Participatory Research | 1 | 2020 | 221 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2013 | 326 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2006 | 2764 | 0.040 |
Why?
|
| Hypesthesia | 1 | 1998 | 107 | 0.040 |
Why?
|
| Energy Metabolism | 2 | 2001 | 2878 | 0.040 |
Why?
|
| Delivery of Health Care | 3 | 2021 | 5334 | 0.040 |
Why?
|
| Drug Hypersensitivity | 1 | 2007 | 917 | 0.040 |
Why?
|
| Osteoporosis | 2 | 2014 | 1604 | 0.040 |
Why?
|
| Melphalan | 2 | 1999 | 420 | 0.040 |
Why?
|
| Health Care Surveys | 2 | 2011 | 2422 | 0.040 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 1998 | 113 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2014 | 2925 | 0.040 |
Why?
|
| Sarcoma | 1 | 2008 | 1800 | 0.040 |
Why?
|
| Rats, Inbred Strains | 2 | 1995 | 2088 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2018 | 247 | 0.040 |
Why?
|
| United States Food and Drug Administration | 2 | 2020 | 1661 | 0.040 |
Why?
|
| Austria | 1 | 2017 | 206 | 0.040 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2006 | 1551 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2022 | 4570 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 2019 | 1624 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2016 | 63 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2018 | 350 | 0.030 |
Why?
|
| Capsules | 2 | 2013 | 191 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2008 | 1896 | 0.030 |
Why?
|
| Sexuality | 1 | 1998 | 180 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2006 | 3205 | 0.030 |
Why?
|
| Mediator Complex Subunit 1 | 1 | 2016 | 30 | 0.030 |
Why?
|
| Boston | 2 | 2007 | 9313 | 0.030 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2016 | 84 | 0.030 |
Why?
|
| Cell Count | 1 | 2020 | 1834 | 0.030 |
Why?
|
| Postoperative Complications | 3 | 2013 | 15609 | 0.030 |
Why?
|
| RNA, Double-Stranded | 1 | 2017 | 294 | 0.030 |
Why?
|
| Knowledge | 1 | 1997 | 177 | 0.030 |
Why?
|
| Life Tables | 1 | 1996 | 364 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 14649 | 0.030 |
Why?
|
| Receptors, Angiotensin | 1 | 1995 | 141 | 0.030 |
Why?
|
| Phosphoserine | 1 | 2016 | 203 | 0.030 |
Why?
|
| Genes, p53 | 2 | 2010 | 712 | 0.030 |
Why?
|
| Cognition | 1 | 2013 | 6988 | 0.030 |
Why?
|
| Drug Approval | 1 | 2022 | 812 | 0.030 |
Why?
|
| ROC Curve | 1 | 2003 | 3575 | 0.030 |
Why?
|
| Casein Kinase II | 1 | 2016 | 122 | 0.030 |
Why?
|
| Body Temperature Regulation | 1 | 1997 | 292 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2019 | 2261 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2005 | 1937 | 0.030 |
Why?
|
| Infusion Pumps, Implantable | 1 | 1996 | 158 | 0.030 |
Why?
|
| Hypertension | 2 | 2014 | 8532 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-3 | 1 | 2015 | 50 | 0.030 |
Why?
|
| Craniotomy | 1 | 2019 | 741 | 0.030 |
Why?
|
| Polymorphism, Genetic | 2 | 1995 | 4242 | 0.030 |
Why?
|
| Thalidomide | 1 | 2000 | 885 | 0.030 |
Why?
|
| Models, Animal | 1 | 2001 | 2108 | 0.030 |
Why?
|
| Heart | 1 | 2008 | 4403 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2007 | 3394 | 0.030 |
Why?
|
| Infertility, Female | 1 | 2000 | 760 | 0.030 |
Why?
|
| Sick Role | 2 | 2008 | 229 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 2016 | 1141 | 0.030 |
Why?
|
| Jews | 1 | 2016 | 356 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1998 | 1056 | 0.030 |
Why?
|
| Integrin alpha4 | 1 | 2014 | 87 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 731 | 0.030 |
Why?
|
| Protein Phosphatase 2 | 1 | 2016 | 231 | 0.030 |
Why?
|
| Directive Counseling | 1 | 2015 | 170 | 0.030 |
Why?
|
| Interferons | 1 | 2017 | 702 | 0.030 |
Why?
|
| RNA Interference | 1 | 2022 | 2829 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 6126 | 0.030 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 18220 | 0.030 |
Why?
|
| Viruses | 1 | 2017 | 374 | 0.030 |
Why?
|
| Employment | 2 | 2005 | 1113 | 0.030 |
Why?
|
| Health Status | 2 | 2005 | 4076 | 0.030 |
Why?
|
| Energy Intake | 2 | 2001 | 2133 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2005 | 3183 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2008 | 6390 | 0.030 |
Why?
|
| Clinical Protocols | 2 | 2009 | 1436 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 1999 | 840 | 0.030 |
Why?
|
| Depressive Disorder | 2 | 2012 | 3735 | 0.030 |
Why?
|
| Eligibility Determination | 1 | 2016 | 421 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2016 | 2803 | 0.030 |
Why?
|
| Tablets | 1 | 2013 | 148 | 0.030 |
Why?
|
| Activities of Daily Living | 2 | 2001 | 2419 | 0.030 |
Why?
|
| Receptor, EphA5 | 1 | 2012 | 10 | 0.030 |
Why?
|
| Medical Records | 1 | 1998 | 1408 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2015 | 506 | 0.030 |
Why?
|
| Case-Control Studies | 4 | 2016 | 22153 | 0.030 |
Why?
|
| Angiotensin II | 1 | 1995 | 849 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 866 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 1333 | 0.030 |
Why?
|
| Income | 1 | 2021 | 1870 | 0.030 |
Why?
|
| Area Under Curve | 1 | 1997 | 1635 | 0.030 |
Why?
|
| RNA | 1 | 2022 | 2713 | 0.030 |
Why?
|
| Postoperative Care | 1 | 1999 | 1467 | 0.030 |
Why?
|
| Receptor, erbB-3 | 1 | 2013 | 143 | 0.030 |
Why?
|
| K562 Cells | 1 | 2014 | 641 | 0.030 |
Why?
|
| Tissue and Organ Procurement | 1 | 2020 | 962 | 0.030 |
Why?
|
| Breast Implants | 1 | 1996 | 407 | 0.030 |
Why?
|
| Platelet Factor 4 | 1 | 2012 | 129 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 1745 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 12966 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2014 | 550 | 0.020 |
Why?
|
| Age Distribution | 1 | 2018 | 2872 | 0.020 |
Why?
|
| Comprehensive Health Care | 1 | 2013 | 123 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2017 | 990 | 0.020 |
Why?
|
| Streptozocin | 1 | 1992 | 193 | 0.020 |
Why?
|
| Health Behavior | 2 | 2008 | 2643 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 658 | 0.020 |
Why?
|
| Cardiovascular Diseases | 3 | 2004 | 15498 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 2015 | 335 | 0.020 |
Why?
|
| Cooperative Behavior | 2 | 2010 | 1505 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 691 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 1827 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 1999 | 1819 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 1768 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 1300 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2021 | 3431 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2016 | 2625 | 0.020 |
Why?
|
| Pregnancy | 2 | 2015 | 29869 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 384 | 0.020 |
Why?
|
| Nomograms | 1 | 2012 | 230 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2021 | 4140 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2020 | 1894 | 0.020 |
Why?
|
| Severity of Illness Index | 4 | 2015 | 15829 | 0.020 |
Why?
|
| Models, Theoretical | 2 | 2006 | 3567 | 0.020 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2014 | 651 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 11458 | 0.020 |
Why?
|
| Micro-Electrical-Mechanical Systems | 1 | 2010 | 30 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 1995 | 4172 | 0.020 |
Why?
|
| Drug Evaluation | 2 | 2007 | 641 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2008 | 5671 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 664 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2016 | 1470 | 0.020 |
Why?
|
| Cardiac Electrophysiology | 1 | 2009 | 59 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2016 | 3606 | 0.020 |
Why?
|
| Karnofsky Performance Status | 1 | 2009 | 166 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 1743 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2018 | 4269 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 2802 | 0.020 |
Why?
|
| Age of Onset | 1 | 2016 | 3303 | 0.020 |
Why?
|
| Economics | 1 | 2010 | 141 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 2001 | 1948 | 0.020 |
Why?
|
| Methyltransferases | 1 | 1992 | 373 | 0.020 |
Why?
|
| Stroke | 1 | 2011 | 9715 | 0.020 |
Why?
|
| Pedigree | 1 | 1997 | 4539 | 0.020 |
Why?
|
| Rats | 4 | 1998 | 23716 | 0.020 |
Why?
|
| Radiotherapy Dosage | 2 | 2006 | 2897 | 0.020 |
Why?
|
| Developing Countries | 1 | 2021 | 2868 | 0.020 |
Why?
|
| Climacteric | 1 | 2008 | 57 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 1997 | 2327 | 0.020 |
Why?
|
| Case Management | 1 | 2010 | 272 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2021 | 3027 | 0.020 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2006 | 4575 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2015 | 2703 | 0.020 |
Why?
|
| Marital Status | 1 | 2010 | 425 | 0.020 |
Why?
|
| Health Surveys | 2 | 2013 | 4036 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 693 | 0.020 |
Why?
|
| Smoking | 2 | 2010 | 9054 | 0.020 |
Why?
|
| Patient-Centered Care | 1 | 1998 | 1419 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 2012 | 645 | 0.020 |
Why?
|
| Antineoplastic Protocols | 1 | 2007 | 48 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2021 | 3743 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2014 | 1320 | 0.020 |
Why?
|
| Child | 2 | 2008 | 80089 | 0.020 |
Why?
|
| Liver | 1 | 2003 | 7512 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2014 | 3088 | 0.020 |
Why?
|
| Polyglutamic Acid | 1 | 2007 | 47 | 0.020 |
Why?
|
| Motivation | 1 | 1997 | 2003 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2016 | 2445 | 0.020 |
Why?
|
| Governing Board | 1 | 2007 | 50 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1703 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2012 | 1130 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2007 | 351 | 0.020 |
Why?
|
| Consent Forms | 1 | 2007 | 55 | 0.020 |
Why?
|
| Prostatic Neoplasms | 2 | 2000 | 11107 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2009 | 2185 | 0.020 |
Why?
|
| Escape Reaction | 1 | 2006 | 57 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 3 | 2007 | 5493 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 934 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2011 | 1217 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 1878 | 0.020 |
Why?
|
| Cytokines | 1 | 2021 | 7373 | 0.020 |
Why?
|
| Arousal | 1 | 2012 | 1171 | 0.020 |
Why?
|
| Freezing | 1 | 2007 | 311 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2007 | 301 | 0.020 |
Why?
|
| Computational Biology | 1 | 2018 | 3509 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2008 | 1057 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2015 | 1375 | 0.020 |
Why?
|
| Fear | 1 | 2015 | 1477 | 0.020 |
Why?
|
| Tocopherols | 1 | 2005 | 44 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 1667 | 0.020 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2006 | 147 | 0.020 |
Why?
|
| Hospitalization | 2 | 2021 | 10708 | 0.020 |
Why?
|
| Cytogenetics | 1 | 2006 | 198 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2013 | 3196 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 1924 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2005 | 6927 | 0.020 |
Why?
|
| Crosses, Genetic | 2 | 1998 | 750 | 0.020 |
Why?
|
| Cell Survival | 1 | 2015 | 5780 | 0.020 |
Why?
|
| Teaching Materials | 1 | 2005 | 84 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 4117 | 0.020 |
Why?
|
| Guideline Adherence | 2 | 2007 | 2218 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2016 | 7583 | 0.020 |
Why?
|
| Medicaid | 2 | 2012 | 2814 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 5463 | 0.020 |
Why?
|
| Radiation Pneumonitis | 1 | 2005 | 102 | 0.020 |
Why?
|
| Cell Line | 1 | 2018 | 15577 | 0.010 |
Why?
|
| Linear Models | 2 | 2010 | 5866 | 0.010 |
Why?
|
| Canada | 1 | 2010 | 2120 | 0.010 |
Why?
|
| Cause of Death | 1 | 2015 | 3683 | 0.010 |
Why?
|
| Quantitative Trait Loci | 1 | 2012 | 2112 | 0.010 |
Why?
|
| Confusion | 1 | 2006 | 278 | 0.010 |
Why?
|
| Authorship | 1 | 2007 | 284 | 0.010 |
Why?
|
| Spirituality | 1 | 2008 | 430 | 0.010 |
Why?
|
| Observer Variation | 1 | 2010 | 2607 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2017 | 3077 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 4533 | 0.010 |
Why?
|
| Models, Statistical | 2 | 2010 | 5074 | 0.010 |
Why?
|
| Protein Binding | 1 | 2016 | 9345 | 0.010 |
Why?
|
| Toremifene | 1 | 2003 | 24 | 0.010 |
Why?
|
| Adiponectin | 1 | 2009 | 1107 | 0.010 |
Why?
|
| Brain | 2 | 2020 | 27100 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2016 | 4937 | 0.010 |
Why?
|
| Genetic Loci | 1 | 2012 | 2624 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2006 | 512 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1990 | 1378 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2007 | 631 | 0.010 |
Why?
|
| Office Visits | 1 | 2007 | 593 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2010 | 2697 | 0.010 |
Why?
|
| New Jersey | 1 | 2003 | 295 | 0.010 |
Why?
|
| Carotenoids | 1 | 2005 | 621 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 4569 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 4745 | 0.010 |
Why?
|
| Nutrition Assessment | 1 | 2005 | 726 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2012 | 6016 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 3794 | 0.010 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2002 | 42 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2008 | 2567 | 0.010 |
Why?
|
| Qualitative Research | 1 | 2013 | 3017 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 2008 | 938 | 0.010 |
Why?
|
| Epoetin Alfa | 1 | 2001 | 78 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2003 | 432 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2015 | 12759 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2005 | 1380 | 0.010 |
Why?
|
| Southeastern United States | 1 | 2000 | 91 | 0.010 |
Why?
|
| Endometrium | 1 | 2003 | 403 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2015 | 6561 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2015 | 14388 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 2003 | 403 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 7050 | 0.010 |
Why?
|
| Aging | 1 | 1999 | 8700 | 0.010 |
Why?
|
| Health Services | 1 | 2005 | 751 | 0.010 |
Why?
|
| Infection Control | 1 | 2007 | 982 | 0.010 |
Why?
|
| Trimetrexate | 1 | 1999 | 15 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2001 | 671 | 0.010 |
Why?
|
| Imides | 1 | 1999 | 15 | 0.010 |
Why?
|
| Naphthalimides | 1 | 1999 | 22 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 2851 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2005 | 1663 | 0.010 |
Why?
|
| Cardiology | 1 | 2010 | 1656 | 0.010 |
Why?
|
| Diet | 1 | 1997 | 8049 | 0.010 |
Why?
|
| Needs Assessment | 1 | 2005 | 1139 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2000 | 748 | 0.010 |
Why?
|
| Cost Savings | 1 | 2004 | 912 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 5780 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 2008 | 1669 | 0.010 |
Why?
|
| Decision Trees | 1 | 2000 | 504 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2000 | 592 | 0.010 |
Why?
|
| Growth Substances | 1 | 2000 | 768 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2021 | 42193 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2000 | 673 | 0.010 |
Why?
|
| Empirical Research | 1 | 1998 | 120 | 0.010 |
Why?
|
| Matrix Metalloproteinases | 1 | 2000 | 391 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2005 | 1808 | 0.010 |
Why?
|
| Health Services Needs and Demand | 1 | 2005 | 1400 | 0.010 |
Why?
|
| Leadership | 1 | 2007 | 1385 | 0.010 |
Why?
|
| Isoquinolines | 1 | 1999 | 352 | 0.010 |
Why?
|
| Lymphokines | 1 | 2000 | 925 | 0.010 |
Why?
|
| Health Policy | 1 | 2009 | 2682 | 0.010 |
Why?
|
| Genetic Research | 1 | 1998 | 171 | 0.010 |
Why?
|
| Risk Management | 1 | 2000 | 557 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 4172 | 0.010 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 1639 | 0.010 |
Why?
|
| Catheter Ablation | 1 | 2010 | 2634 | 0.010 |
Why?
|
| Drug Resistance | 2 | 1992 | 1594 | 0.010 |
Why?
|
| Women | 1 | 1998 | 224 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2006 | 2909 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2006 | 2164 | 0.010 |
Why?
|
| Rats, Inbred WKY | 1 | 1995 | 150 | 0.010 |
Why?
|
| Rats, Inbred SHR | 1 | 1995 | 186 | 0.010 |
Why?
|
| Genomic Library | 1 | 1995 | 189 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2006 | 5863 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2010 | 4392 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1995 | 422 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2001 | 1524 | 0.010 |
Why?
|
| Absorption | 1 | 1994 | 242 | 0.010 |
Why?
|
| Base Sequence | 2 | 1995 | 12420 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2001 | 1300 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2007 | 5965 | 0.010 |
Why?
|
| Biological Availability | 1 | 1994 | 389 | 0.010 |
Why?
|
| Half-Life | 1 | 1994 | 650 | 0.010 |
Why?
|
| Adenine | 1 | 1999 | 985 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2007 | 2894 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1995 | 1376 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 1995 | 783 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2006 | 3356 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1995 | 17630 | 0.010 |
Why?
|
| Contrast Media | 1 | 2006 | 5305 | 0.010 |
Why?
|
| Software | 1 | 2006 | 4432 | 0.010 |
Why?
|
| Counseling | 1 | 2000 | 1538 | 0.010 |
Why?
|
| X Chromosome | 1 | 1995 | 816 | 0.010 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 1992 | 83 | 0.010 |
Why?
|
| Genes | 1 | 1995 | 1823 | 0.010 |
Why?
|
| Species Specificity | 1 | 1995 | 2410 | 0.010 |
Why?
|
| DNA Primers | 1 | 1995 | 2817 | 0.010 |
Why?
|
| Genome | 1 | 1998 | 1737 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1992 | 860 | 0.000 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2000 | 4340 | 0.000 |
Why?
|
| Electrocardiography | 1 | 2002 | 6346 | 0.000 |
Why?
|
| Caregivers | 1 | 2000 | 2241 | 0.000 |
Why?
|
| Random Allocation | 1 | 1990 | 2392 | 0.000 |
Why?
|
| Dietary Fats | 1 | 1993 | 1995 | 0.000 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1995 | 8165 | 0.000 |
Why?
|
| Private Practice | 1 | 1985 | 153 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1992 | 2604 | 0.000 |
Why?
|
| Membrane Glycoproteins | 1 | 1992 | 3688 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1999 | 7403 | 0.000 |
Why?
|